Quantitative Evaluation of Semaglutide-Associated Changes in Gastric Antral Motility Using Oral Contrast-Enhanced Gastric Ultrasonography
5 affiliations
- 1Department of Ultrasound Medicine
- 2Department of Medical Imaging
- 3Department of Gastroenterology
- 4Department of Endocrinology
- 5Ultrasound Department
Abstract
Li-Yun Xu,1,* Dong Han,2,* Yuan-Min Zhu,3 Song Dong,4 Lin Li,3 Cui-Xia Liu,1 Jun Guo5 1Department of Ultrasound Medicine, Beijing Changping Hospital of Traditional Chinese Medicine, Beijing, 102200, People’s Republic of China; 2Department of Medical Imaging, Beijing Changping Hospital of Traditionnal Chinese Medicine, Beijing, 102200, People’s Republic of China; 3Department of Gastroenterology, Aerospace Center Hospital, Beijing, 100000, People’s Republic of China; 4Department of Endocrinology, Aerospace Center Hospital, Beijing, 100049, People’s Republic of China; 5Ultrasound Department, Aerospace Center Hospital, Beijing, 100000, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jun Guo, Ultrasound Department, Aerospace Center Hospital, No. 15 Yuquan Road, Haidian Dist, Beijing, 100049, People’s Republic of China, Tel +86 010-59971199, Email [email protected]: To quantitatively evaluate changes in gastric antral motility before and after semaglutide administration using oral contrast-enhanced gastric ultrasonography, providing imaging-based quantitative evidence for assessing the gastrointestinal effects of semaglutide in clinical practice.Methods: This prospective study enrolled 60 patients with obesity or diabetes mellitus who were randomly assigned to the semaglutide or control group. Gastric ultrasonography was performed at baseline, 4 weeks, and 8 weeks. Concurrently, a gastrointestinal transit test was conducted: patients ingested a barium marker capsule when 200 mL of contrast agent remained, with abdominal radiography performed at 2 and 4 hours post-ingestion.Results: No significant between-group differences were observed at baseline. At 4 weeks following semaglutide injection, all gastric motility indices were significantly reduced (p < 0.05), with further significant decreases at 8 weeks (p < 0.05). Gastrointestinal transit tests demonstrated progressively increased retention of barium markers in the stomach, an elevated gastric transit index, and a decreased barium excretion rate in the semaglutide group compared with the control group (all p < 0.05).Conclusion: Oral contrast-enhanced gastric ultrasonography provides a noninvasive, quantitative method for assessing semaglutide-associated delayed gastric emptying and reduced gastric antral motility. These effects intensify with prolonged treatment duration.Keywords: gastric antral motility, gastric ultrasonography, gastrointestinal transit test, oral gastric ultrasound contrast agent, semaglutide, delayed gastric emptying
Related
- The added value of contrast-enhanced ultrasonography to BI-RADS in the evaluation of breast lesions presenting with pathological nipple discharge
- Pigmented purpura dermatosis associated with compounded semaglutide: A case report and literature review of medication-associated pigmented purpuric dermatosis
- Cutaneous Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Systematic Review
- Interactive Panometry: Using Proximal Balloon Distension During Functional Lumen Imaging Probe Panometry to Enhance Motility Evaluation of Inhibitory Function
- Hemodynamic Compromise Due to Semaglutide-Associated Abdominal Distension
BibTeX
@article{xu2026quantitative,
title = {{Quantitative Evaluation of Semaglutide-Associated Changes in Gastric Antral Motility Using Oral Contrast-Enhanced Gastric Ultrasonography}},
author = {Xu LY and Han D and Zhu YM and Dong S and Li L and Liu CX and Guo J},
journal = {Risk Management and Healthcare Policy},
year = {2026},
month = nov,
url = {https://www.dovepress.com/quantitative-evaluation-of-semaglutide-associated-changes-in-gastric-a-peer-reviewed-fulltext-article-RMHP},
note = {CC BY},
}
RIS
TY - JOUR
TI - Quantitative Evaluation of Semaglutide-Associated Changes in Gastric Antral Motility Using Oral Contrast-Enhanced Gastric Ultrasonography
AU - Xu LY
AU - Han D
AU - Zhu YM
AU - Dong S
AU - Li L
AU - Liu CX
AU - Guo J
PY - 2026
DA - 2026/11/15
JO - Risk Management and Healthcare Policy
UR - https://www.dovepress.com/quantitative-evaluation-of-semaglutide-associated-changes-in-gastric-a-peer-reviewed-fulltext-article-RMHP
AB - Li-Yun Xu,1,* Dong Han,2,* Yuan-Min Zhu,3 Song Dong,4 Lin Li,3 Cui-Xia Liu,1 Jun Guo5 1Department of Ultrasound Medicine, Beijing Changping Hospital of Traditional Chinese Medicine, Beijing, 102200, People’s Republic of China; 2Department of Medical Imaging, Beijing Changping Hospital of Traditionnal Chinese Medicine, Beijing, 102200, People’s Republic of China; 3Department of Gastroenterology, Aerospace Center Hospital, Beijing, 100000, People’s Republic of China; 4Department of Endocrinology, Aerospace Center Hospital, Beijing, 100049, People’s Republic of China; 5Ultrasound Department, Aerospace Center Hospital, Beijing, 100000, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jun Guo, Ultrasound Department, Aerospace Center Hospital, No. 15 Yuquan Road, Haidian Dist, Beijing, 100049, People’s Republic of China, Tel +86 010-59971199, Email [email protected]: To quantitatively evaluate changes in gastric antral motility before and after semaglutide administration using oral contrast-enhanced gastric ultrasonography, providing imaging-based quantitative evidence for assessing the gastrointestinal effects of semaglutide in clinical practice.Methods: This prospective study enrolled 60 patients with obesity or diabetes mellitus who were randomly assigned to the semaglutide or control group. Gastric ultrasonography was performed at baseline, 4 weeks, and 8 weeks. Concurrently, a gastrointestinal transit test was conducted: patients ingested a barium marker capsule when 200 mL of contrast agent remained, with abdominal radiography performed at 2 and 4 hours post-ingestion.Results: No significant between-group differences were observed at baseline. At 4 weeks following semaglutide injection, all gastric motility indices were significantly reduced (p < 0.05), with further significant decreases at 8 weeks (p < 0.05). Gastrointestinal transit tests demonstrated progressively increased retention of barium markers in the stomach, an elevated gastric transit index, and a decreased barium excretion rate in the semaglutide group compared with the control group (all p < 0.05).Conclusion: Oral contrast-enhanced gastric ultrasonography provides a noninvasive, quantitative method for assessing semaglutide-associated delayed gastric emptying and reduced gastric antral motility. These effects intensify with prolonged treatment duration.Keywords: gastric antral motility, gastric ultrasonography, gastrointestinal transit test, oral gastric ultrasound contrast agent, semaglutide, delayed gastric emptying
SN - 1179-1594
ER -